Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A phase 1 trial found that adding SCLC-directed chemotherapy to osimertinib didn't prevent small cell lung cancer transformation in patients with EGFR/TP53/RB1 triple-mutant lung cancer. Nearly half (45%) still underwent SCLC transformation, with outcomes similar to osimertinib alone. The findings raise fresh questions about the best timing and treatment strategy for this high-risk group.
A phase 1 study published in Science Translational Medicine tested whether adding platinum-etoposide chemotherapy to osimertinib could prevent small cell lung cancer (SCLC) transformation in patients with metastatic EGFR/TP53/RB1 triple-mutant non-small cell lung cancer — a group known to be at elevated risk for this histologic shift. The answer, unfortunately, was no.
Eleven patients enrolled at Memorial Sloan Kettering Cancer Center received osimertinib for 9 weeks, followed by carboplatin or cisplatin plus etoposide, then osimertinib monotherapy until progression. Despite the combination approach, 45% of patients still transformed to SCLC, and survival outcomes were comparable to osimertinib monotherapy alone. Genomic analysis also confirmed that TP53/RB1 co-mutations are reliable biomarkers for predicting both overt and occult SCLC transformation.
By the Numbers:
Why it matters: For oncologists managing triple-mutant lung cancer, this study signals that preemptive SCLC-directed chemo isn't the answer — and that better-timed or entirely different interventions may be needed to tackle this challenging transformation.